Production (Stage)
Eton Pharmaceuticals, Inc.
ETON
$14.30
-$0.21-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 48.38% | 12.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 48.38% | 12.81% | |||
| Cost of Revenue | 43.51% | 28.57% | |||
| Gross Profit | 52.27% | 2.76% | |||
| SG&A Expenses | 45.49% | 19.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 67.42% | 8.03% | |||
| Operating Income | -145.02% | 105.11% | |||
| Income Before Tax | -193.15% | -202.00% | |||
| Income Tax Expenses | -14.94% | 169.05% | |||
| Earnings from Continuing Operations | -162.88% | -195.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -162.88% | -195.37% | |||
| EBIT | -145.02% | 105.11% | |||
| EBITDA | -59.14% | 68.87% | |||
| EPS Basic | -155.46% | -194.63% | |||
| Normalized Basic EPS | -1,413.04% | -119.01% | |||
| EPS Diluted | -110.43% | -239.00% | |||
| Normalized Diluted EPS | -1,413.04% | -119.49% | |||
| Average Basic Shares Outstanding | 2.87% | 0.91% | |||
| Average Diluted Shares Outstanding | 2.87% | -1.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||